Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AAV2hAQP1

Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx, LLC

Phase 1 Most advanced trial (none active)
MGTX Developer
1 Registered trials

What is AAV2hAQP1?

AAV2hAQP1 is an adeno-associated virus serotype 2 vector carrying the human aquaporin 1 gene, delivered into the parotid gland through Stensen's duct. It is intended to restore water transport in salivary gland cells, and it is studied in radiation-induced parotid gland hypofunction and xerostomia in patients with head and neck cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Pathways
water transport across salivary gland acinar cell membranes
Therapy area
Oncology
Developer
MeiraGTx, LLC (MGTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04043104 Phase 1 Radiation-Induced Parotid Gland Hypofunction Completed MGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck CancerRadiation-Induced Parotid Gland HypofunctionXerostomia Due to Radiotherapy

More from MeiraGTx, LLC

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.

Follow MGTX, the company behind AAV2hAQP1

See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.